Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.-MedSci.cn

Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.

Quinn, DI; Zhang, T; Gurney, H; Doshi, GK; Cobb, PW; Parnis, F; Lee, JL; Park, SH; Semenov, A; Chang, WYH; Powles, T; Wan, S; Poehlein, CH; Choueiri, TK

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (6):

科室
- - 订阅+
  - 更多科室
工具
服务